Fermenta Biotech Ltd (FERMENTA) — Announcement | 8 September 2026

· BSE Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
Fermenta Biotech signs exclusive licence with VIT Vellore for Vitamin B12 fortification technology
🔮 What's Next
advancing technology towards market-ready applications

Fermenta Biotech announced an exclusive licence agreement with VIT Vellore to commercialise a technology that fortifies Vitamin B12 during natural fermentation of foods like curd and idli, potentially expanding its nutritional ingredients portfolio and addressing widespread deficiency in vegetarian diets.

📄 View Original Announcement (PDF)

About Fermenta Biotech Ltd (FERMENTA)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹1,379.87 Cr P/E: 22.7 ROE: 14.3% ROCE: 18.1% Div Yield: 0.80%

View full FERMENTA stock details →

📡 Get AI alerts when FERMENTA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track FERMENTA — Free

📊 More FERMENTA filings

See all FERMENTA filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when FERMENTA files new disclosures

Track FERMENTA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track FERMENTA — Free

Free account · 2 AI queries/day